Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ856856,50,18
KB766,57670,46
PKN58,2558,27-4,29
Msft438,724391,88
Nokia3,78753,7920,44
IBM216,25216,80,82
Mercedes-Benz Group AG59,4759,493,21
PFE29,8729,890,44
19.09.2024 12:17:36
Indexy online
AD Index online
select
AD Index online
 

  • 19.09.2024 12:00:19
IONBEAM APPL (IBAB.BR, Brussels)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
13,56 -0,59 -0,08 93 681
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2024
Popis společnosti
Obecné informace
Název společnostiIon Beam Applications SA
TickerIBAB
Kmenové akcie:Ordinary Shares
RICIBAB.BR
ISINBE0003766806
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 30.06.2024 1 844
Akcie v oběhu k 30.06.2024 29 181 437
MěnaEUR
Kontaktní informace
UliceChemin du Cyclotron 3
MěstoLOUVAIN-LA-NEUVE
PSČ1348
ZeměBelgium
Kontatní osoba 
Funkce kontaktní osoby 
Telefon3 210 475 811
Fax3210475810

Business Summary: Ion Beam Applications SA (IBA) is a Belgium-based company that develops and markets technologies, pharmaceutical products and tailored solutions for the healthcare sector, with emphasis on cancer diagnosis and therapy. IBA is also active in the sterilization and ionization field. The Company operates through two business segments, namely the pharmaceuticals segment, which includes radiopharmaceuticals and the equipments segment, which encompasses proton therapy, particle accelerators and dosimetry. Through its various subsidiaries, Ion Beam Applications SA is active in a number of countries, including Belgium, Germany, France, Italy, Spain, the United Kingdom, Sweden, the United States, India and China. In November 2013, the Company announced the closing of the sale of 100% of its business unit Cisbio Bioassays.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Ion Beam Applications SA revenues increased 22% to EUR206.5M. Net loss decreased 62% to EUR10.3M. Revenues reflect Protontherapy segment increase of 30% to EUR177.8M. Lower net loss reflects Protontherapy segment loss decrease of 83% to EUR4.1M. Basic Earnings per Share excluding Extraordinary Items increased from -EUR0.94 to -EUR0.35.
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Advanced Medical Equipment
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSIrradiation Apparatus Manufacturing
NAICSAll Other Miscellaneous Electrical Equipment and Component Manufacturing
NAICSSurgical Appliance and Supplies Manufacturing
NAICS2007Irradiation Apparatus Mfg
NAICS2007All Oth Misc Electrical Equip & Component Mfg
NAICS2007Surgical Appliance & Supplies Mfg
NAICS1997Irradiation Apparatus Manufacturing
NAICS1997All Other Miscellaneous Electrical Equipment and Component Manufacturing
NAICS1997Surgical Appliance and Supplies Manufacturing
SICX-Ray Apparatus And Tubes
SICElectrical Equip/supplies, Nec
SICSurgical Appliances And Supplies



  • Poslední aktualizace: 19.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the Board, Representing Saint-Denis SAPierre Mottet-01.01.1988
Chief Executive Officer, Managing Director and Inside Director, Representative of Lamaris Group SRLOlivier Legrain-09.05.2012
Chief Financial Officer, Member of the Management BoardSoumya Chandramouli-01.06.2016
Chief Human Resource and Sustainability Officer, Member of the Management BoardFrederic Nolf-
Chief Research Officer, Managing Director, Internal Director, Representing Technofutur SAYves Jongen-01.01.1986